Stay updated on Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The page now presents details of the completed Phase 3 tildrakizumab study for moderate-to-severe plaque psoriasis, including its design, eligibility criteria, outcome measures, publications, and record dates.
    Difference
    70%
    Check dated 2026-11-07T12:43:45.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0 while the page continued to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:21:31.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH website changes and says agencies are using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T17:46:43.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The revision identifier in the footer changed from v3.7.1 to v3.7.2; the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T17:23:48.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The site revision displayed in the footer changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T18:18:31.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the full study content with an access-denied view. This reflects a page-access issue rather than an update to study data.
    Difference
    21%
    Check dated 2026-09-19T22:21:06.000Z thumbnail image

Stay in the know with updates to Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.